Reverse transcriptase-IN-1

• UNSPSC Description:

  Reverse transcriptase-IN-1 (Compound 12z), a diarylbenzopyrimidine (DABP) analogue, is a potent, orally active HIV-1 nonnucleoside reverse transcriptase inhibitor. Reverse transcriptase-IN-1 has antiviral activity with EC50 values of 3.4 nM, 4.3 nM and 3.6 nM for HIV-1 IIIB, E138K and K103N mutants, respectively. Reverse transcriptase-IN-1 also has an IC50of 13.7 nM against HIV-1 reverse transcriptase enzyme[1].

• Target Antigen:

  HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/reverse-transcriptase-in-1.html

• Purity:

  98.08

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  N#CC1=CC=C(NC2=NC(NC3=C([N+]([O-])=O)C=C(/C=C/C#N)C=C3C)=C4C=CC=CC4=N2)C=C1

• Molecular Weight:

  447.45

• References & Citations:

  [1]Han S, et al. Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles. ACS Infect Dis. 2019 Oct 24.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2380001-43-2